Identification of Residues 286 and 289 as Critical for Conferring Substrate Specificity of Human CYP2C9 for Diclofenac and Ibuprofen

This publication has 14 references indexed in Scilit:

• An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians
  Pharmacogenetics, 1998
• The Substrate Binding Site of Human Liver Cytochrome P450 2C9: An NMR Study
  Biochemistry, 1997
• Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C
  Biochemical Pharmacology, 1997
• The role of the CFP2C9-Leu 359 allelic variant in the tolbutamide polymorphism
  Pharmacogenetics, 1996
• Interaction of Sulfaphenazole Derivatives with Human Liver Cytochromes P450 2C: Molecular Origin of the Specific Inhibitory Effects of Sulfaphenazole on CYP 2C9 and Consequences for the Substrate Binding Site Topology of CYP 2C9
  Biochemistry, 1996
• A Universal Approach to the Expression of Human and Rabbit Cytochrome P450s of the 2C Subfamily inEscherichia coli
  Archives of Biochemistry and Biophysics, 1995
• Biochemistry and molecular biology of the human CYP2C subfamily
  Pharmacogenetics, 1994
• Evidence That CYP2C19 is the Major (S)-Mephenytoin 4'-Hydroxylase in Humans
  Biochemistry, 1994
• Site-directed mutagenesis of virtually any plasmid by eliminating a unique site
  Analytical Biochemistry, 1992
• Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily
  Biochemistry, 1991